Skip to main content

Table 2 Linear regression analyses between CSF and serum ACE measures and log-transformed CSF biomarkers in the total population ( n= 118)

From: The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease

  Model Ln Aβ42 Ln tau Ln ptau
CSF ACE protein levela 1 0.12 (0.05; 0.19)** 0.10 (-0.01; 0.22) 0.14 (0.05; 0.22)**
2 0.09 (0.04; 0.15)** 0.15 (0.06; 0.25)** 0.17 (0.10; 0.25)**
3 0.11 (0.05; 0.16)** 0.16 (0.05; 0.26)** 0.19 (0.10; 0.27)**
CSF ACE activityb 1 0.07 (-0.00; 0.14) -0.06 (-0.18; 0.06) 0.02 (-0.07; 0.11)
2 0.05 (-0.00; 0.11) -0.03 (-0.13; 0.07) 0.04 (-0.04; 0.12)
3 0.06 (0.00; 0.11)* -0.04 (-0.14; 0.06) 0.03 (-0.05; 0.11)
Serum ACE protein levelc 1 0.09 (0.02; 0.17)* -0.09 (-0.21; 0.03) -0.02 (-0.11; 0.07)
2 0.06 (-0.00; 0.12) -0.03 (-0.13; 0.07) 0.02 (-0.06; 0.10)
3 0.04 (-0.02; 0.11) -0.04 (-0.15; 0.06) 0.02 (-0.06; 0.11)
Serum ACE activityd 1 0.06 (-0.01; 0.14) -0.10 (-0.22; 0.01) -0.02 (-0.10; 0.07)
2 0.03 (-0.03; 0.09) -0.05 (-0.15; 0.05) 0.02 (-0.06; 0.10)
3 0.02 (-0.04; 0.08) -0.06 (-0.17; 0.05) 0.01 (-0.08; 0.10)
  1. Data presented as Β (95% confidence interval). Model 1: unadjusted. Model 2: adjusted for age, sex and study groups. Model 3: additionally adjusted for APOE-ϵ4 genotype, systolic blood pressure, diastolic blood pressure, body mass index, smoking, history of hypercholesterolemia and diabetes mellitus. Aβ, amyloid-beta; ACE, angiotensin-converting enzyme; CSF, cerebrospinal fluid; Ln, log-transformed; ptau, tau phosphorylated at threonine 181; RFU, relative fluorescence units; tau, total tau. *P < 0.05, **P < 0.01. aPer standard deviation increase (1.32 ng/ml). bPer standard deviation increase (59 RFU). cPer standard deviation increase (1.30 ng/ml). dPer standard deviation increase (133 RFU).